Immuneering (IMRX) Net Equity Issued and Repurchased (2020 - 2025)

Immuneering's Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $1081.0 for Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased fell 97.11% year-over-year to $1081.0 in Q4 2025; TTM through Mar 2026 was $1.3 million, a 92.74% decrease from a year earlier, with the FY2025 full-year figure at $25.0 million, up 489.98% from the prior year.
• Net Equity Issued and Repurchased retreated to $1081.0 in Q4 2025 per IMRX's latest filing, from $1.3 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $95.5 million in Q3 2021 and bottomed at -$28.2 million in Q4 2023.
• The 4-year median for Net Equity Issued and Repurchased is $1.3 million (2025), against an average of $12.4 million.
• Across the five-year window, Net Equity Issued and Repurchased jumped 100.13% in 2024 and tumbled 97.11% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $95.5 million in 2021, then sank by 129.52% to -$28.2 million in 2023, then surged by 100.13% to $37397.0 in 2024, then tumbled by 97.11% to $1081.0 in 2025.
• Per Business Quant, the three latest IMRX Net Equity Issued and Repurchased figures stand at $1081.0 (Q4 2025), $1.3 million (Q3 2025), and $13.7 million (Q1 2025).